Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 6/20 | 0.56 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.56 |
| ▸ | PGR | P06401 | 1/20 | 0.56 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.56 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.55 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.53 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.53 |
| ▸ | LMNA | P02545 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.53 |
| ▸ | ALB | P02768 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 1/20 | 0.53 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.53 |
| ▸ | RARB | P10826 | 1/20 | 0.53 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.53 |
| ▸ | HTR2A | P28223 | 1/20 | 0.53 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.53 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11570387 | 1.00 | PTGS2 (0.56) | PTGS2PTGS1PGRADORA3SLC6A2 | |
| SCHEMBL5833971 | 0.84 | PTGS2 (0.54) | PTGS2PTGS1PGRADORA3SLC6A2 | |
| SCHEMBL27456673 | 0.84 | KMT2A (0.53) | PTGS2PTGS1LMNAAKR1C3AKR1C2 | |
| SCHEMBL12742311 | 0.82 | HPGD (0.51) | PTGS2 | |
| SCHEMBL5833974 | 0.82 | PTGS2 (0.52) | PTGS2PTGS1PGRADORA3SLC6A2 | |
| SCHEMBL10944721 | 0.81 | LMNA (0.60) | PTGS2PTGS1PGRADORA3SLC6A2 | |
| SCHEMBL13524217 | 0.81 | L3MBTL1 (0.57) | EPHX1CXCR1CXCR2TSHRTRPV1 | |
| SCHEMBL14201191 | 0.81 | PTGS2 (0.72) | PTGS2PTGS1PGRADORA3SLC6A2 | |
| SCHEMBL753603 | 0.80 | PTGS1 (0.60) | PTGS2PTGS1LMNAALOX5 | |
| SCHEMBL13557330 | 0.80 | HPGD (0.49) | PTGS2LMNAAKR1C3AKR1C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 81 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116768796-A | Novel pyrazole-3-carboxamide derivative and preparation method and application thereof | 河北农业大学 | 2023-09-19 | — | — | CN | claimed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | claimed |
| EP-1599175-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA Pharma AG (DE) | 2005-11-30 | — | — | EP | claimed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | claimed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | claimed |
| WO-2004071391-A2 | IMIDAZOPYRIDINES CONTAINING COMBINATIONS AND THEIR USE IN TREATING GASTROINTESTINAL INFLAMMATORY DISORDERS | ALTANA PHARMA AG (DE) | 2004-08-26 | — | — | WO | claimed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | claimed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | claimed |
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | CLEARSIDE BIOMEDICAL, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| CN-117024317-B | Fluobenil preparation method of examination | 浙江荣耀生物科技股份有限公司 | 2025-12-23 | — | — | CN | disclosed |
| US-20250345206-A1 | APPARATUS AND METHODS FOR OCULAR INJECTION | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-11-13 | — | — | US | disclosed |
| CN-120398730-A | Fluobenil preparation method of examination | 上海贝美医药科技有限公司 | 2025-08-01 | — | — | CN | disclosed |
| US-12350261-B2 | Methods and devices for the treatment of ocular diseases in human subjects | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250186253-A1 | DEVICES AND METHODS FOR ADJUSTING THE INSERTION DEPTH OF A NEEDLE FOR MEDICAMENT DELIVERY | CLEARSIDE BIOMEDICAL, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20060154954-A1 | Combinations and use of selected pharmaceutically active compounds | ALTANA PHARMA AG (DE) | 2006-07-13 | — | — | US | disclosed |
| WO-2005074930-A1 | PHARMACEUTICAL COMBINATIONS OF (S) -PANTOPRAZOLE WITH NSAID OR CORTICOSTEROIDS | ALTANA PHARMA AG (DE) | 2005-08-18 | — | — | WO | disclosed |
| US-20040242597-A1 | Combination | NYCOMED GMBH (DE) | 2004-12-02 | — | — | US | disclosed |
| EP-1429807-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA Pharma AG (DE) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003024489-A2 | COMBINATION OF A NSAID AND A PDE-4 INHIBITOR | ALTANA PHARMA AG (DE) | 2003-03-27 | — | — | WO | disclosed |
| US-4134989-A | ANALGESICS, ANTIINFLAMMATORY AGENTS, ANTIPYRETIC, ANTISEPTIC, EXPECTORATING AGENTS | AZIENDE CHIMICHE RIUNITE ANGELINI FRANCESCO A.C.R.A.F. S.P.A. (IT) | 1979-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260144674-A1 | Apparatus and Methods for Drug Delivery Using Microneedles | PROKR2, SLC10A2, GLP1R | PTGS2 2731/4885PTGS1 3480/4885PGR 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.